• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Associations between ACE-Inhibitors, Angiotensin Receptor Blockers, and Lean Body Mass in Community Dwelling Older Women.社区居住老年女性中血管紧张素转换酶抑制剂、血管紧张素受体阻滞剂与去脂体重之间的关联
J Aging Res. 2018 Feb 19;2018:8491092. doi: 10.1155/2018/8491092. eCollection 2018.
2
ARB users exhibit a lower fracture incidence than ACE inhibitor users among older hypertensive men.ARB 用户在老年高血压男性中比 ACEI 用户的骨折发生率更低。
Age Ageing. 2017 Jan 10;46(1):57-64. doi: 10.1093/ageing/afw150.
3
Angiotensin-Converting Inhibitors and Angiotensin II Receptor Blockers and Longitudinal Change in Percent Emphysema on Computed Tomography. The Multi-Ethnic Study of Atherosclerosis Lung Study.血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂与 CT 上肺气肿百分比的纵向变化。动脉粥样硬化肺研究的多民族研究。
Ann Am Thorac Soc. 2017 May;14(5):649-658. doi: 10.1513/AnnalsATS.201604-317OC.
4
Risk of Osteoporotic Fractures With Angiotensin II Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors in Hypertensive Community-Dwelling Elderly.社区居住的老年高血压患者中,血管紧张素II受体阻滞剂与血管紧张素转换酶抑制剂相比,发生骨质疏松性骨折的风险
J Bone Miner Res. 2014 Nov;29(11):2483-8. doi: 10.1002/jbmr.2271.
5
Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Blockers With Severity of COVID-19: A Multicenter, Prospective Study.血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂与 COVID-19 严重程度的关联:一项多中心前瞻性研究。
J Cardiovasc Pharmacol Ther. 2021 May;26(3):244-252. doi: 10.1177/1074248420976279. Epub 2020 Nov 24.
6
Renin-Angiotensin System Blockers and Adverse Outcomes of Influenza and Pneumonia: A Danish Cohort Study.肾素-血管紧张素系统阻滞剂与流感和肺炎不良结局的关系:一项丹麦队列研究。
J Am Heart Assoc. 2020 Oct 20;9(19):e017297. doi: 10.1161/JAHA.120.017297. Epub 2020 Oct 1.
7
Treatment of hypertension with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and resting metabolic rate: A cross-sectional study.血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂治疗高血压与静息代谢率:一项横断面研究。
J Clin Hypertens (Greenwich). 2021 Dec;23(12):2106-2114. doi: 10.1111/jch.14392. Epub 2021 Nov 30.
8
Characteristics of patients prescribed angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the combination at an urban medical center.在一家城市医疗中心开具血管紧张素转换酶抑制剂、血管紧张素受体阻滞剂或两者联合用药的患者特征。
MedGenMed. 2007 Nov 20;9(4):40.
9
Long-term persistence to mono and combination therapies with angiotensin converting enzymes and angiotensin II receptor blockers in Australia.澳大利亚使用血管紧张素转换酶抑制剂和血管紧张素II受体阻滞剂进行单药治疗和联合治疗的长期持续性。
Eur J Clin Pharmacol. 2016 Jun;72(6):765-71. doi: 10.1007/s00228-016-2037-x. Epub 2016 Mar 10.
10
Lean body mass change over 6 years is associated with dietary leucine intake in an older Danish population.在丹麦老年人群中,6年期间的去脂体重变化与膳食亮氨酸摄入量有关。
Br J Nutr. 2016 May;115(9):1556-62. doi: 10.1017/S0007114516000611. Epub 2016 Mar 16.

引用本文的文献

1
Interrelationship of Sarcopenia and Cardiovascular Diseases: A Review of Potential Mechanisms and Management.肌少症与心血管疾病的相互关系:潜在机制和管理的综述。
J ASEAN Fed Endocr Soc. 2024;39(1):69-78. doi: 10.15605/jafes.039.01.03. Epub 2023 Oct 27.
2
Associations Between Hypertension, Angiotensin-Converting Enzyme Inhibitors, and Physical Performance in Very Old Adults: Results from the ilSIRENTE Study.高龄老年人高血压、血管紧张素转换酶抑制剂与身体机能之间的关联:来自ilSIRENTE研究的结果
J Frailty Aging. 2024;13(2):74-81. doi: 10.14283/jfa.2024.15.
3
Is sarcopenia an associated factor of increased administration of specific medications in patients with heart failure? A systematic review and meta-analysis.肌肉减少症是心力衰竭患者特定药物使用增加的相关因素吗?一项系统评价和荟萃分析。
Front Cardiovasc Med. 2024 Jan 25;11:1293537. doi: 10.3389/fcvm.2024.1293537. eCollection 2024.
4
ACE I/D genotype associates with strength in sarcopenic men but not with response to ACE inhibitor therapy in older adults with sarcopenia: Results from the LACE trial.ACE I/D基因型与肌肉减少症男性的肌力相关,但与老年肌肉减少症患者对ACE抑制剂治疗的反应无关:LACE试验结果
PLoS One. 2023 Oct 20;18(10):e0292402. doi: 10.1371/journal.pone.0292402. eCollection 2023.
5
Resistance training with or without nutritional supplementation showed no influence on muscle thickness in old-institutionalized adults: a secondary analysis of the Vienna Active Ageing Study.抗阻训练联合或不联合营养补充对老年机构居住成年人肌肉厚度均无影响:维也纳积极老龄化研究的二次分析。
Eur J Phys Rehabil Med. 2022 Aug;58(4):646-654. doi: 10.23736/S1973-9087.22.06436-X. Epub 2022 May 16.
6
Rewinding sarcopenia: a narrative review on the renin-angiotensin system.逆转肌肉减少症:肾素-血管紧张素系统的叙述性综述。
Aging Clin Exp Res. 2021 Sep;33(9):2379-2392. doi: 10.1007/s40520-020-01761-3. Epub 2021 Jan 4.

本文引用的文献

1
2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.2016年美国心脏病学会/美国心脏协会/美国心力衰竭学会关于心力衰竭新药物治疗的聚焦更新:2013年美国心脏病学会基金会/美国心脏协会心力衰竭管理指南的更新:美国心脏病学会/美国心脏协会临床实践指南工作组和美国心力衰竭学会的报告
J Am Coll Cardiol. 2016 Sep 27;68(13):1476-1488. doi: 10.1016/j.jacc.2016.05.011. Epub 2016 May 20.
2
Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia.治疗或预防肌肉减少症药物的临床试验开展建议。
Aging Clin Exp Res. 2016 Feb;28(1):47-58. doi: 10.1007/s40520-015-0517-y. Epub 2015 Dec 30.
3
Angiotensin II Receptor Blocker Neprilysin Inhibitor (ARNI): New Avenues in Cardiovascular Therapy.血管紧张素 II 受体阻滞剂脑啡肽酶抑制剂(ARNI):心血管治疗的新途径。
High Blood Press Cardiovasc Prev. 2015 Sep;22(3):241-6. doi: 10.1007/s40292-015-0112-5. Epub 2015 Jun 23.
4
ACE inhibitors, statins and thiazides: no association with change in grip strength among community dwelling older men and women from the Hertfordshire Cohort Study.血管紧张素转换酶抑制剂、他汀类药物和噻嗪类药物:来自赫特福德郡队列研究的社区居住老年男性和女性握力变化与之无关。
Age Ageing. 2014 Sep;43(5):661-6. doi: 10.1093/ageing/afu008. Epub 2014 Feb 11.
5
2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).2014 年成人高血压管理的循证指南:第八届联合国家委员会(JNC 8)任命的专家组报告。
JAMA. 2014 Feb 5;311(5):507-20. doi: 10.1001/jama.2013.284427.
6
An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention.控制高血压的有效方法:美国心脏协会、美国心脏病学会和疾病控制与预防中心的科学咨询意见。
Hypertension. 2014 Apr;63(4):878-85. doi: 10.1161/HYP.0000000000000003. Epub 2013 Nov 15.
7
Molecular mechanisms and signaling pathways of angiotensin II-induced muscle wasting: potential therapeutic targets for cardiac cachexia.血管紧张素 II 诱导肌肉减少症的分子机制和信号通路:心脏恶病质的潜在治疗靶点。
Int J Biochem Cell Biol. 2013 Oct;45(10):2322-32. doi: 10.1016/j.biocel.2013.05.035. Epub 2013 Jun 13.
8
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.2013年美国心脏病学会基金会/美国心脏协会实践指南工作组关于心力衰竭管理的指南:美国心脏病学会基金会/美国心脏协会报告
J Am Coll Cardiol. 2013 Oct 15;62(16):e147-239. doi: 10.1016/j.jacc.2013.05.019. Epub 2013 Jun 5.
9
Statins, angiotensin-converting enzyme inhibitors, and physical performance in older women.他汀类药物、血管紧张素转换酶抑制剂与老年女性的身体机能
J Am Geriatr Soc. 2012 Dec;60(12):2206-14. doi: 10.1111/jgs.12029. Epub 2012 Nov 23.
10
Relationship between diabetes risk and admixture in postmenopausal African-American and Hispanic-American women.绝经后非裔美国人和西班牙裔美国女性的糖尿病风险与混合之间的关系。
Diabetologia. 2012 May;55(5):1329-37. doi: 10.1007/s00125-012-2486-4. Epub 2012 Feb 10.

社区居住老年女性中血管紧张素转换酶抑制剂、血管紧张素受体阻滞剂与去脂体重之间的关联

Associations between ACE-Inhibitors, Angiotensin Receptor Blockers, and Lean Body Mass in Community Dwelling Older Women.

作者信息

Bea Jennifer W, Wassertheil-Smoller Sylvia, Wertheim Betsy C, Klimentidis Yann, Chen Zhao, Zaslavsky Oleg, Manini Todd M, Womack Catherine R, Kroenke Candyce H, LaCroix Andrea Z, Thomson Cynthia A

机构信息

University of Arizona Cancer Center, 1515 N. Campbell Ave, P.O. Box 245024, Tucson, AZ 85724-0524, USA.

Department of Epidemiology and Population Health, Albert Einstein College of Medicine of Yeshiva University, 1300 Morris Park Avenue, Belfer Building, Room 1308B, Bronx, NY 10461, USA.

出版信息

J Aging Res. 2018 Feb 19;2018:8491092. doi: 10.1155/2018/8491092. eCollection 2018.

DOI:10.1155/2018/8491092
PMID:29670769
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5836326/
Abstract

Studies suggest that ACE-inhibitors (ACE-I) and angiotensin receptor blockers (ARBs) may preserve skeletal muscle with aging. We evaluated longitudinal differences in lean body mass (LBM) among women diagnosed with hypertension and classified as ACE-I/ARB users and nonusers among Women's Health Initiative participants that received dual energy X-ray absorptiometry scans to estimate body composition (=10,635) at baseline and at years 3 and 6 of follow-up. Of those, 2642 were treated for hypertension at baseline. Multivariate linear regression models, adjusted for relevant demographics, behaviors, and medications, assessed ACE-I/ARB use/nonuse and LBM associations at baseline, as well as change in LBM over 3 and 6 years. Although BMI did not differ by ACE-I/ARB use, LBM (%) was significantly higher in ACE-I/ARB users versus nonusers at baseline (52.2% versus 51.3%, resp., =0.001). There was no association between ACE-I/ARB usage and change in LBM over time. Reasons for higher LBM with ACE-I/ARB use cross sectionally, but not longitundinally, are unclear and may reflect a threshold effect of these medications on LBM that is attenuated over time. Nevertheless, ACE-I/ARB use does not appear to negatively impact LBM in the long term.

摘要

研究表明,血管紧张素转换酶抑制剂(ACE-I)和血管紧张素受体阻滞剂(ARB)可能随着衰老过程保护骨骼肌。我们评估了女性健康倡议参与者中被诊断为高血压且分为ACE-I/ARB使用者和非使用者的女性之间瘦体重(LBM)的纵向差异,这些参与者在基线以及随访的第3年和第6年接受了双能X线吸收法扫描以估计身体成分(n = 10,635)。其中,2642人在基线时接受高血压治疗。多变量线性回归模型在调整了相关人口统计学、行为和药物因素后,评估了基线时ACE-I/ARB的使用/未使用情况与LBM的关联,以及3年和6年期间LBM的变化。尽管BMI在ACE-I/ARB使用者和非使用者之间没有差异,但在基线时,ACE-I/ARB使用者的LBM(%)显著高于非使用者(分别为52.2%和51.3%,P = 0.001)。ACE-I/ARB的使用与LBM随时间的变化之间没有关联。ACE-I/ARB使用导致LBM在横断面时较高但在纵向时并非如此的原因尚不清楚,可能反映了这些药物对LBM的阈值效应,这种效应会随着时间减弱。然而,从长期来看,ACE-I/ARB的使用似乎不会对LBM产生负面影响。